2026-526117-28-00Not yet recruitingPhase 1/2
Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 17 Aug 2026
- Start date
- 19 Oct 2026
- Lead sponsor
- Sanofi-Aventis Recherche & Developpement
- Diseases
- Lupus (SLE), Rheumatoid arthritis
- EU CT number
- 2026-526117-28-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 10
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with refractory systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It tests the safety and early effect of SAR447998.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Refractory systemic lupus erythematosus or rheumatoid arthritis.
Read by machine on 9 Nov 2026.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Regional De Marseille | Marseille | France | Not yet recruiting |
| Centre Hospitalier Universitaire De Montpellier | Montpellier Cedex 5 | France | Not yet recruiting |
| Centre Hospitalier Universitaire de Bordeaux | Pessac | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.